Patents by Inventor Benoit Polack

Benoit Polack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ATTENUATED AND ADAPTED STRAIN OF PSEUDOMONAS FOR DELIVERING ANTIGENS
    Publication number: 20170114319
    Abstract: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and lasl in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become “killed but metabolically active.
    Type: Application
    Filed: January 3, 2017
    Publication date: April 27, 2017
    Applicants: UNIVERSITE GRENOBLES ALPES, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE
    Inventors: Audrey LE GOUELLEC, Bertrand TOUSSAINT, Benoit POLACK
  • Procoagulant molecular decoy for treating hemophilia A or B with or without inhibitor
    Patent number: 9493761
    Abstract: The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: November 15, 2016
    Assignees: UNIVERSITE JOSEPH FOURIER (GRENOBLE 1), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Benoit Polack, Aline Thomas
  • GLA-DOMAINLESS FACTOR X
    Publication number: 20160177286
    Abstract: The present invention relates to a protein consisting of the sequence SEQ ID No.: 11 or 25 or 26, directly bound, or bound via a linker, especially -Arg-Lys-Arg-, to the sequence SEQ ID No.: 6.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 23, 2016
    Applicants: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS, UNIVERSITE GRENOBLE I JOSEPH FOURIER
    Inventors: Aline Thomas, Marie-Claire Dagher, Raphael Marlu, Benoit Polack, Jean-Luc Plantier, Alexandre Fontayne, Toufik Abache
  • NOVEL PROCOAGULANT MOLECULAR DECOY FOR TREATING HEMOPHILIA A OR B WITH OR WITHOUT INHIBITOR
    Publication number: 20140050716
    Abstract: The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor.
    Type: Application
    Filed: February 29, 2012
    Publication date: February 20, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE JOSEPH FOURIER (GRENOBLE 1)
    Inventors: Benoit Polack, Aline Thomas
  • Tool for the transfer and production of proteins using the pseudomonas type III secretion system
    Patent number: 7939319
    Abstract: The present invention provides a vector for expression of a chimeric protein which is the result of the fusion between the N-terminal end of ExoS of Pseudomonas aeruginosa and an amino acid sequence of interest, the N-terminal end of ExoS corresponding to the N-terminal end of the chimeric protein. The vector contains the following from 5? to 3?: a promoter, a nucleic acid comprising a nucleotide sequence encoding at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS; or any sequence of the same size that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS, a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of interest.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: May 10, 2011
    Assignee: Universite Joseph Fourier
    Inventors: Benoit Polack, Bertrand Toussaint, Lauriane Quenee
  • Tool for the transfer and production of proteins using the pseudomonas type III secretion system
    Publication number: 20080187520
    Abstract: The present invention provides a vector for expression of a chimeric protein which is the result of the fusion between the N-terminal end of ExoS of Pseudomonas aeruginosa and an amino acid sequence of interest, the N-terminal end of ExoS corresponding to the N-terminal end of the chimeric protein. The vector contains the following from 5? to 3?: a promoter, a nucleic acid comprising a nucleotide sequence encoding at least the 48 (SEQ ID 4) and at the most the 96 (SEQ ID 6) amino acids of the N-terminal end of ExoS; or any sequence of the same size that is at least 70% identical thereto and that has a secretion activity at the same level as that of ExoS, a nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of interest.
    Type: Application
    Filed: May 12, 2006
    Publication date: August 7, 2008
    Applicant: Universite Joseph Fourier
    Inventors: Benoit Polack, Bertrand Toussaint, Lauriane Quenee